Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
+0.4×
Gilead Sciences logo
Gilead SciencesGILD
+0.6×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
18×+2.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
6.1×+1.2×

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$912.8M+55.1%
Enterprise value$904.32M+54.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

Based on the most recent quarter.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's current ratio?
Sana Biotechnology (SANA) reported current ratio of 1.3× in Q1 2026.
How has Sana Biotechnology's current ratio changed year-over-year?
Sana Biotechnology's current ratio decreased by 61.9% year-over-year, from 3.4× to 1.3×.
What is the long-term trend for Sana Biotechnology's current ratio?
Over 5 years (2020 to 2025), Sana Biotechnology's current ratio has grown at a -31.2% compound annual growth rate (CAGR), from 12.2× to 1.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.